Verastem, Inc. (VSTM): Price and Financial Metrics

Verastem, Inc. (VSTM): $0.44

0.00 (-0.25%)

POWR Rating

Component Grades













Add VSTM to Watchlist
Sign Up

Industry: Biotech



in industry


  • Sentiment is the dimension where VSTM ranks best; there it ranks ahead of 98.74% of US stocks.
  • The strongest trend for VSTM is in Stability, which has been heading up over the past 159 days.
  • VSTM's current lowest rank is in the Momentum metric (where it is better than 4.74% of US stocks).

VSTM Stock Summary

  • With a price/sales ratio of 33.24, VERASTEM INC has a higher such ratio than 95.43% of stocks in our set.
  • With a year-over-year growth in debt of 751.1%, VERASTEM INC's debt growth rate surpasses 97.64% of about US stocks.
  • In terms of volatility of its share price, VSTM is more volatile than 93.72% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to VERASTEM INC, a group of peers worth examining would be ATNM, AGLE, PRTC, EXEL, and SGTX.
  • Visit VSTM's SEC page to see the company's official filings. To visit the company's web site, go to

VSTM Valuation Summary

  • In comparison to the median Healthcare stock, VSTM's EV/EBIT ratio is 109.16% lower, now standing at -0.6.
  • Over the past 136 months, VSTM's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for VSTM.

Stock Date P/S P/B P/E EV/EBIT
VSTM 2023-03-17 35.3 1.9 -1.2 -0.6
VSTM 2023-03-16 34.9 1.9 -1.2 -0.6
VSTM 2023-03-15 33.2 1.8 -1.2 -0.5
VSTM 2023-03-14 33.2 1.8 -1.2 -0.5
VSTM 2023-03-13 30.1 1.5 -1.3 -0.6
VSTM 2023-03-10 26.1 1.3 -1.1 -0.4

VSTM Growth Metrics

    Its 2 year revenue growth rate is now at -82.52%.
  • Its 2 year price growth rate is now at -37.7%.
  • Its 3 year price growth rate is now at -39.68%.
Over the past 49 months, VSTM's revenue has gone down $22,367,000.

The table below shows VSTM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 3.141 -56.99 -73.485
2022-06-30 3.143 -52.735 -78.181
2022-03-31 3.643 -53.465 -73.131
2021-12-31 2.053 -53.502 -71.2
2021-09-30 2.014 -65.272 -74.583
2021-06-30 80.659 -9.698 -38.659

VSTM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VSTM has a Quality Grade of C, ranking ahead of 63.22% of graded US stocks.
  • VSTM's asset turnover comes in at 0.015 -- ranking 380th of 682 Pharmaceutical Products stocks.
  • NERV, BLUE, and OTLC are the stocks whose asset turnover ratios are most correlated with VSTM.

The table below shows VSTM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.015 0.994 -0.646
2021-06-30 0.510 0.602 -0.382
2021-03-31 0.478 0.611 -0.535
2020-12-31 0.455 0.619 -0.911
2020-09-30 0.476 0.624 -1.030
2020-06-30 0.118 0.856 -1.060

VSTM Price Target

For more insight on analysts targets of VSTM, see our VSTM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.25 Average Broker Recommendation 1.38 (Strong Buy)

VSTM Stock Price Chart Interactive Chart >

Price chart for VSTM

VSTM Price/Volume Stats

Current price $0.44 52-week high $2.13
Prev. close $0.44 52-week low $0.29
Day low $0.42 Volume 266,000
Day high $0.44 Avg. volume 788,519
50-day MA $0.55 Dividend yield N/A
200-day MA $0.75 Market Cap 87.92M

Verastem, Inc. (VSTM) Company Bio

Verastem, Inc. focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. The company was founded in 2010 and is based in Needham, Massachusetts.

VSTM Latest News Stream

Event/Time News Detail
Loading, please wait...

VSTM Latest Social Stream

Loading social stream, please wait...

View Full VSTM Social Stream

Latest VSTM News From Around the Web

Below are the latest news stories about VERASTEM INC that investors may wish to consider to help them evaluate VSTM as an investment opportunity.

New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer

BOSTON, March 15, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the launch of Let’s Talk About LGSOC, a new initiative that calls attention to low-grade serous ovarian cancer (LGSOC). Let’s Talk About LGSOC provides detailed information about LGSOC and its symptoms, its differences from the more common high-grade serous ovarian cancer (HGSOC), tips and resources, and ways to connect with others

Yahoo | March 15, 2023

Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

BOSTON, March 14, 2023--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2022, and highlighted recent progress.

Yahoo | March 14, 2023

Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers

BOSTON, February 02, 2023--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today outlined key strategic priorities and upcoming catalysts to support its lead compound RAF/MEK clamp avutometinib in RAS pathway-driven cancers.

Yahoo | February 2, 2023

Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock?

Verastem (VSTM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | January 30, 2023

Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock

BOSTON, January 24, 2023--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has entered into a definitive agreement to sell approximately 2.1 million shares of its Series B Convertible Preferred Stock (the "Preferred Stock") to affiliates of BVF Partners L.P. in a private placement to raise aggregate gross proceeds of up to approximately $60 million in two tranches, before deducting fees to the plac

Yahoo | January 24, 2023

Read More 'VSTM' Stories Here

VSTM Price Returns

1-mo -11.79%
3-mo 28.65%
6-mo -52.30%
1-year -64.23%
3-year -79.82%
5-year -85.85%
YTD 9.32%
2022 -80.37%
2021 -3.76%
2020 58.96%
2019 -60.12%
2018 9.45%

Continue Researching VSTM

Here are a few links from around the web to help you further your research on Verastem Inc's stock as an investment opportunity:

Verastem Inc (VSTM) Stock Price | Nasdaq
Verastem Inc (VSTM) Stock Quote, History and News - Yahoo Finance
Verastem Inc (VSTM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8859 seconds.